Altano Capital

Altano Capital maintains a thin public footprint — a website and LinkedIn presence with limited disclosure of thesis, geography, fund size, or stage focus. For healthcare AI founders, this opacity should be treated as informative: there is no public evidence that Altano is a healthcare specialist or that it has invested in clinical AI, biotech, or medtech. Treat them as a generalist private capital firm of unclear size. The most plausible check size is in the lower end of seed and bridge rounds, likely $250K to $1M, slotting in alongside a primary-led syndicate rather than leading. Founders who should approach: those with a warm introduction from someone inside Altano’s network, particularly if your company is a software-led business with healthcare applications and you need a flexible co-investor to fill a round. Founders who should not approach: regulated medical devices, biotech, and any company that will need deep healthcare-specialist follow-on capital, since Altano cannot credibly anchor that journey. The realistic entry path is LinkedIn outreach to the partners listed on their company page, paired with a referral from a known co-investor. Without a thesis disclosure, founders should treat any first call as a fact-finding exercise: ask directly which sectors they have backed, what stage, and which co-investors they syndicate with. If the answer reveals no relevant healthcare track record, redeploy your fundraising calendar to investors with demonstrated healthcare conviction. Be honest with yourself about whether Altano’s check is worth the time.